AMN Healthcare price target lowered to $22 from $33 at Citizens JMP

Citizens JMP analyst Constantine Davides lowered the firm’s price target on AMN Healthcare (AMN) to $22 from $33 and keeps an Outperform rating on the shares. AMN’s Q2 revenue exceeded the firm’s estimates, and Citizens is encouraged by stable Q3 order and extension trends to-date following the impact from broader secular uncertainty in May and June, the analyst tells investors in a research note. While near-term staffing trends may remain choppy, the longer-term risk/reward profile of shares remains attractive, the firm says.